ArticleLung India : official organ of Indian Chest Society2026
Chronicity and comorbidities: Is estimated longer duration of obstructive sleep apnoea linked to higher cardiometabolic risk?
Article in Lung India : official organ of Indian Chest Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesObstructive sleep apnea (OSA) is associated with an increased risk of cardiometabolic disorders. Still, the role of OSA duration in the development and severity of these conditions remains unclear. This study aimed to evaluate the association between estimated OSA duration and cardio-metabolic comorbidities. MATERIALS AND
methodsIn this cross-sectional study, 279 adults (≥35 years; body mass index ≥20 kg/m 2 ) with moderate-severe OSA diagnosed by level-1 polysomnography were included. Diagnosis of cardiometabolic disorders was based on examination, medical records, and laboratory investigations. Duration of OSA was estimated using the OSA-Onset algorithm, and comorbidity prevalence was compared across tertiles of estimated duration.
resultsIn this cross-sectional exploratory analysis, the median estimated OSA duration was 18.7 years, and the median estimated age of onset was 32.3 years. Systemic hypertension was the most prevalent comorbidity (79.6%) and showed a higher prevalence across tertiles of estimated OSA duration (68.8%, 83.9%, and 86%, respectively; P = 0.007). In multivariable models, estimated OSA duration was statistically associated with hypertension (odds ratio [OR] 1.039, 95% confidence interval [CI] 1.012-1.068; P = 0.005). Sensitivity analysis excluding participants with implausible negative onset estimates yielded similar results (OR 1.036, 95% CI 1.006-1.066; P = 0.017). No statistically significant associations were observed for other cardiometabolic conditions. Given multiple comparisons and correlated outcomes, findings should be interpreted as exploratory.
conclusionIn this cross-sectional exploratory study, longer algorithm-estimated OSA duration was statistically associated with hypertension but not with other cardiometabolic comorbidities. These findings are hypothesis-generating and require confirmation in longitudinal studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.